Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Status:
Terminated
Trial end date:
2019-10-10
Target enrollment:
Participant gender:
Summary
This is a study to determine the safety, tolerability and maximum tolerated dose of
Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL)
amyloidosis patients.